Precision and Innovation: Sylvester Comprehensive Cancer Center at ASTRO 2025
Summary
- Sylvester Comprehensive Cancer Center is making a significant impact at the American Society for Radiation Oncology (ASTRO) 2025 annual meeting.
- Sylvester radiation oncologists will use the meeting to showcase innovative treatments and personalized approaches that are transforming cancer care.
- Miller School of Medicine radiation oncology professor and chair Dr. Markus Bredel will present new approaches to treating neurological conditions with advanced imaging and radiosurgery techniques.
Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, is making a significant impact at the American Society for Radiation Oncology (ASTRO) 2025 annual meeting.
The conference, held in San Francisco, brings together leading experts, researchers and trainees in radiation oncology from around the world. Sylvester’s strong presence highlights its commitment to advancing cancer care, research and education.
This year, radiation oncologists from Sylvester will be at the forefront, delivering key presentations that showcase their ongoing impact on the field.
“Our presence at ASTRO this year is a testament to our relentless pursuit of precision and progress in radiation medicine,” said Markus Bredel, M.D., Ph.D., professor and chair of the Miller School’s Department of Radiation Oncology. “Our teams are not only advancing the science but also reimagining how we deliver care to improve outcomes for every patient.”
The presentations from Sylvester will cover a range of critical topics, from innovative treatment modalities to personalized approaches that are transforming cancer care. Sylvester researchers will be highlighted as moderators, as well as presenters of poster and oral presentations.
About ASTRO
ASTRO is the world’s largest gathering of radiation oncology professionals, drawing more than 11,000 attendees each year, including radiation oncologists, medical physicists, dosimetrists, radiation therapists, oncology nurses, researchers and industry representatives.
This year’s theme is “Rediscovering Radiation Medicine and Exploring New Indications,” with a focus on the latest advancements in radiation therapy, patient care and cancer research. Attendees will benefit from scientific sessions, keynote lectures, technology showcases, hands-on workshops and networking events.
The meeting features groundbreaking research, clinical trials, educational panels and an exhibit hall with more than 200 exhibitors presenting leading-edge medical devices and solutions for cancer treatment.
Leadership in Radiation Oncology
Dr. Bredel will present at the Presidential Symposium, focusing on “Precision without Incision: The New Era of Functional Radiosurgery.” His session, “Classical Movement Disorders and Connectomics: Image-Guided Radiosurgery Reimagined,” explores innovative approaches to treating neurological conditions with advanced imaging and radiosurgery techniques.
“Advances in image-guided radiosurgery are transforming how we approach neurological disorders, allowing us to deliver precision treatment without invasive procedures,” said Dr. Bredel. “Our work is redefining the boundaries of what’s possible in radiation medicine and improving outcomes for patients with complex movement disorders.”
Additionally:
• Amanda Rivera, M.D., a Sylvester researcher and assistant professor of radiation oncology, will discuss gaps in gynecologic cancer care.
• Alan Dal Pra, M.D., a Sylvester researcher, associate professor of radiation oncology and director of clinical research, will explore biomarker breakthroughs in prostate cancer as a discussant at the conference.
• In a plenary session, Matthew Abramowitz, M.D., associate professor of radiation oncology, will also be featured as a discussant.
Leading-Edge Research and Student Contributions
Sylvester’s commitment to fostering innovation and supporting the next generation of cancer researchers and clinicians is reflected in its research presentations. Alexandra Dreyfuss, M.D., will present a prospective, multicenter, phase II study on pembrolizumab and involved-site radiation therapy for Hodgkin lymphoma, highlighting new protocols and clinical trials that are shaping the future of hematologic radiation therapy.
“As radiation oncology continues to evolve with advances in precision medicine, technology and patient-centered care, Sylvester remains at the forefront,” said Dr. Bredel.
Tags: ASTRO, cancer research, Dr. Markus Bredel, Newsroom, Radiation oncology, Sylverster Comprehensive Cancer Center